New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 30.7mg equivalent to upadacitinib 30 mg - modified release tablet - 30 mg - active: upadacitinib hemihydrate 30.7mg equivalent to upadacitinib 30 mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry red 85f150093 tartaric acid - rinvoq is indicated for the treatment of adults and adolescents 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - risankizumab 150 mg/ml;   - solution for injection - 150 mg/ml - active: risankizumab 150 mg/ml   excipient: glacial acetic acid polysorbate 20 sodium acetate trihydrate trehalose dihydrate water for injection - psoriatic arthritis: skyrizi is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease modifying antirheumatic drugs (dmards). skyrizi may be used as monotherapy or in combination with a conventional synthetic disease modifying antirheumatic drug (csdmard).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - risankizumab 150 mg/ml;   - solution for injection - 150 mg/ml - active: risankizumab 150 mg/ml   excipient: glacial acetic acid polysorbate 20 sodium acetate trihydrate trehalose dihydrate water for injection - psoriatic arthritis: skyrizi is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease modifying antirheumatic drugs (dmards). skyrizi may be used as monotherapy or in combination with a conventional synthetic disease modifying antirheumatic drug (csdmard).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 46.1mg equivalent to upadacitinib 45 mg - modified release tablet - 45 mg - active: upadacitinib hemihydrate 46.1mg equivalent to upadacitinib 45 mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry yellow 85f120063 tartaric acid - rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - risankizumab 60 mg/ml - concentrate for infusion - 600 mg/10ml - active: risankizumab 60 mg/ml excipient: glacial acetic acid polysorbate 20 sodium acetate trihydrate trehalose dihydrate water for injection - skyrizi is indicated for the treatment of moderate to severe active crohn's disease in patients 16 years of age and older, who have an inadequate response, a lost response, an intolerance or a contra-indication to either conventional or biologic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir,ombitasvir,paritaprevir,ribavirin,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir sodium monohydrate,ombitasvir,paritaprevir,ribavirin,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir sodium monohydrate,ombitasvir,paritaprevir,ritonavir -

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - levobupivacaine hcl - injection - 2.5 mg/ml - levobupivacaine hcl 2.5 mg/ml

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - levobupivacaine hcl - injection - 5 mg/ml - levobupivacaine hcl 5 mg/ml